Clinical evaluation shows chimeric antigen receptor T cells targeting CD19 induce remission in refractory acute lymphoblastic leukemia, highlighting potential against resistant disease.
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.
No takes yet. Share an insight, caveat, or question.
Maude et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: